Financial Architects (New Jersey)’s Jazz Pharmaceuticals JAZZ Stock Holding History

Financial Architects (New Jersey)’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-3	Closed	–	–	1335
2019 Q1	$0	Buy	+3	New	+$391	﹤0.01%	1471
2018 Q1	–	Sell	-1,000	Closed	-$135K	–	1494
2017 Q4	$135K	Buy	+1,000	New	+$139K	0.02%	420
2017 Q2	–	Sell	-2,000	Closed	-$290K	–	1565
2017 Q1	$290K	Sell	2,000 -4,000	-67%	-$521K	0.05%	216
2016 Q4	$654K	Buy	6,000 +834	+16%	+$92.9K	0.15%	116
2016 Q3	$627K	Buy	5,166 +3,400	+193%	+$458K	0.17%	113
2016 Q2	$249K	Buy	1,766 +1,570	+801%	+$231K	0.07%	199
2016 Q1	$26K	Buy	+196	New	+$24.4K	0.01%	534
2015 Q3	–	Sell	-152	Closed	-$27K	–	571
2015 Q2	$27K	Hold	152	–	–	0.01%	567
2015 Q1	$26K	Buy	152 +22	+17%	+$3.78K	0.01%	525
2014 Q4	$21K	Hold	130	–	–	0.01%	526
2014 Q3	$21K	Sell	130 -475	-79%	-$73K	0.01%	463
2014 Q2	$89K	Buy	+605	New	+$83.9K	0.04%	242

Other funds holding JAZZ

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Financial Architects (New Jersey)'s JAZZ Position: Q2 2019 in Review

Financial Architects (New Jersey) sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2019, closing a stake of 3 shares.

Financial Architects (New Jersey) first reported a position in JAZZ in Q2 2014 and held it in 12 quarters. The position peaked at $654K in Q4 2016. 416 funds tracked by Wall St. Rank hold JAZZ as of Q2 2019.

Financial Architects (New Jersey) reported no remaining Jazz Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
Financial Architects (New Jersey) sold 3 Jazz Pharmaceuticals shares in Q2 2019.
Financial Architects (New Jersey) first reported a position in Jazz Pharmaceuticals in Q2 2014 and held it in 12 quarters.
Financial Architects (New Jersey)'s Jazz Pharmaceuticals position peaked at $654K in Q4 2016.
416 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2019.

Based on Financial Architects (New Jersey)'s 13F filing for Q2 2019, filed 14 Aug 2019.